OncoZenge AB (FRA:8LY) Price-to-Operating-Cash-Flow : (As of Jun. 01, 2025)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Price-to-Operating-Cash-Flow?

As of today (2025-06-01), OncoZenge AB's share price is €0.454. OncoZenge AB's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.06. Hence, OncoZenge AB's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for OncoZenge AB's Price-to-Operating-Cash-Flow or its related term are showing as below:

FRA:8LY's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.165
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

OncoZenge AB's Cash Flow from Operations per share for the three months ended in Mar. 2025 was €-0.02. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.06.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -22.50% per year.

During the past 5 years, OncoZenge AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was -22.50% per year. The lowest was -22.50% per year. And the median was -22.50% per year.

OncoZenge AB Price-to-Operating-Cash-Flow Historical Data

The historical data trend for OncoZenge AB's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Price-to-Operating-Cash-Flow Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of OncoZenge AB's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, OncoZenge AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

OncoZenge AB Price-to-Operating-Cash-Flow Calculation

OncoZenge AB's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.454	/	-0.064
	=

OncoZenge AB's Share Price of today is €0.454.
OncoZenge AB's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.06.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

OncoZenge AB Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

ONCOZ:Sweden

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines